Thermo Fisher Scientific (NYSE: TMO) has reached a definitive agreement to acquire Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, with the news nudging its share 1.26% higher to $267.13 in early afternoon trading on Monday.
The transaction, valued at approximately $1.7 billion in cash, is expected to be completed by the end of the second quarter of 2019, and is subject to customary closing conditions, including regulatory approvals.
Headquartered in Cambridge, Massachusetts, Brammer Bio is a leading viral vector contract development and manufacturing organization (CDMO), enabling biopharma customers to deliver breakthrough medicines to patients by unleashing the potential of gene therapies and gene-modified cell therapies. The business has nearly 600 employees at primary locations in Massachusetts and Florida.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze